Gideon Bollag Opna BioUSA

Time	Session

17:30 18:15	Plenary Session - From Bench to Bedside and Back: the development and FDA approval of vemurafenib for melanoma patients Johanna AJoyce Co-Chair Ludwig Institute for Cancer ResearchSwitzerland YardenaSamuels Co-Chair Weizmann Institute of ScienceIsrael Learnings from RAF inhibitor drug discovery Gideon Bollag Speaker Opna BioUSA Resistance to BRAF Inhibition: Consequences and Therapeutic Opportunities Darrin Stuart Speaker Antares TherapeuticsUnited States Learning the biology of BRAF mutant cancers from the determinants of therapeutic resistance KeithFlaherty Speaker Harvard University, Mass General InstituteUSA Discussion Room P1+2+3

Time

Session

17:30

18:15

Plenary Session - From Bench to Bedside and Back: the development and FDA approval of vemurafenib for melanoma patients

Johanna AJoyce Co-Chair Ludwig Institute for Cancer ResearchSwitzerland

YardenaSamuels Co-Chair Weizmann Institute of ScienceIsrael

Room P1+2+3